Related Experiment Video
Updated: Mar 18, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
Marklie Munroe1, Jill Kolesar2
1School of Pharmacy, University of Wisconsin-Madison, Madison, WI.
Purpose:
The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of olaparib, a first-in-class treatment for advanced treatment-refractory ovarian cancer, are reviewed.
Summary:
Olaparib (Lynparza, AstraZeneca) is an oral inhibitor of poly(ADP-ribose) polymerase (PARP) proteins that play a key role in DNA repair and genomic stability. Olaparib is indicated for use in treating certain patients with advanced, recurrent ovarian cancer who have mutations of the breast cancer 1 gene (BRCA1) or breast cancer 2 gene (BRCA2). In patients with BRCA-mutated cancers, olaparib blocks vital PARP-mediated tumor cell DNA repair mechanisms, leading to "synthetic lethality" and selective tumor cell death. In Phase II clinical trials including patients with platinum-sensitive, platinum-resistant, and platinum-refractory ovarian cancers, olaparib significantly improved progression-free survival, with similar rates of response reported in patients with BRCA1- and BRCA2-mutated disease. Olaparib is generally well tolerated; the most commonly reported adverse events in clinical trials were mild nausea, fatigue, vomiting, and diarrhea. Severe anemia and severe fatigue can occur in association with olaparib treatment. Concurrent administration of olaparib and strong or moderate inducers or inhibitors of cytochrome P-450 isozyme 3A should be avoided, as use of those agents may alter plasma concentrations of olaparib.
Conclusion:
Olaparib is a novel PARP inhibitor that is efficacious and well tolerated in patients with BRCA-mutated advanced ovarian cancers who have received three or more lines of prior treatment.
Insights
Olaparib is an effective PARP inhibitor for advanced ovarian cancer with BRCA mutations. This treatment offers improved progression-free survival and is generally well-tolerated by patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian cancer remains a significant challenge, particularly in advanced, treatment-refractory stages.
- Genetic mutations, such as in BRCA1 and BRCA2 genes, play a critical role in ovarian cancer development and progression.
- Poly(ADP-ribose) polymerase (PARP) proteins are crucial for DNA repair and maintaining genomic stability.
Purpose of the Study:
- To review the pharmacology, clinical efficacy, safety, dosage, administration, and therapeutic role of olaparib.
- To evaluate olaparib as a first-in-class treatment for advanced, treatment-refractory ovarian cancer.
Main Methods:
- Review of existing literature on olaparib.
- Analysis of Phase II clinical trial data for olaparib in ovarian cancer patients.
- Assessment of olaparib's mechanism of action, targeting PARP proteins in BRCA-mutated cancers.
Main Results:
- Olaparib significantly improved progression-free survival in Phase II trials across platinum-sensitive, resistant, and refractory ovarian cancers.
- Similar response rates were observed in patients with BRCA1- and BRCA2-mutated ovarian cancers.
- Olaparib is generally well-tolerated, with common side effects including nausea, fatigue, vomiting, and diarrhea. Severe anemia and fatigue are possible.
Conclusions:
- Olaparib is a novel and efficacious oral PARP inhibitor for patients with BRCA-mutated advanced ovarian cancers.
- It is well-tolerated and offers a valuable therapeutic option for patients who have undergone three or more prior treatment lines.
- Olaparib induces synthetic lethality in tumor cells by inhibiting DNA repair mechanisms, leading to selective cancer cell death.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies